Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study
Top Cited Papers
Open Access
- 2 April 2019
- Vol. 365, l1161
- https://doi.org/10.1136/bmj.l1161
Abstract
OBJECTIVE To quantify the effect on cervical disease at age 20 years of immunisation with bivalent human papillomavirus (HPV) vaccine at age 12-13 years. DESIGN Retrospective population study, 1988-96. SETTING National vaccination and cervical screening programmes in Scotland. PARTICIPANTS 138 692 women born between 1 January 1988 and 5 June 1996 and who had a smear test result recorded at age 20. MAIN OUTCOME MEASURES Effect of vaccination on cytology results and associated histological diagnoses from first year of screening (while aged 20), calculated using logistic regression. RESULTS 138 692 records were retrieved. Compared with unvaccinated women born in 1988, vaccinated women born in 1995 and 1996 showed an 89% reduction (95% confidence interval 81% to 94%) in prevalent cervical intraepithelial neoplasia (CIN) grade 3 or worse (from 0.59% (0.48% to 0.71%) to 0.06% (0.04% to 0.11%)), an 88% reduction (83% to 92%) in CIN grade 2 or worse (from 1.44% (1.28% to 1.63%) to 0.17% (0.12% to 0.24%)), and a 79% reduction (69% to 86%) in CIN grade 1 (from 0.69% (0.58% to 0.63%) to 0.15% (0.10% to 0.21%)). Younger age at immunisation was associated with increasing vaccine effectiveness: 86% (75% to 92%) for CIN grade 3 or worse for women vaccinated at age 12-13 compared with 51% (28% to 66%) for women vaccinated at age 17. Evidence of herd protection against high grade cervical disease was found in unvaccinated girls in the 1995 and 1996 cohorts. CONCLUSIONS Routine vaccination of girls aged 12-13 years with the bivalent HPV vaccine in Scotland has led to a dramatic reduction in preinvasive cervical disease. Evidence of clinically relevant herd protection is apparent in unvaccinated women. These data are consistent with the reduced prevalence of high risk HPV in Scotland. The bivalent vaccine is confirmed as being highly effective vaccine and should greatly reduce the incidence of cervical cancer. The findings will need to be considered by cervical cancer prevention programmes worldwide.Keywords
This publication has 33 references indexed in Scilit:
- Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia--Nationwide Follow-up of Young Danish WomenJNCI Journal of the National Cancer Institute, 2014
- Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal)The Lancet, 2013
- Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impactBMC Infectious Diseases, 2013
- Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage studyBMC Medicine, 2013
- Achieving high and equitable coverage of adolescent HPV vaccine in ScotlandJournal of Epidemiology and Community Health, 2013
- Declining Rates of High-Grade Cervical Lesions in Young Women in Connecticut, 2008–2011Cancer Epidemiology, Biomarkers & Prevention, 2013
- Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological studyThe Lancet, 2011
- Evaluation of type-specific HPV persistence and high-risk HPV viral load quantitation in HPV positive women under 30 with normal cervical cytologyJournal of Medical Virology, 2011
- The proposed BSCC terminology for abnormal cervical cytology.Cytopathology, 2008
- CIN2 Is a Much Less Reproducible and Less Valid Diagnosis than CIN3International Journal of Gynecological Pathology, 2007